Table 1.
Delayed treatment*
|
Peginterferon beta1a 125 μg
|
|||
---|---|---|---|---|
Every 2 weeks (n = 228) | Every 4 weeks (n = 227) | Every 2 weeks (n = 512) | Every 4 weeks (n = 501) | |
Anti-IFN beta1a BAb positive, n (%) | 1 (<1) | 7 (3) | 16 (3) | 8 (2) |
Antipeginterferon beta1a NAb positive, n (%)** | 0 | 3 (1) | 8 (2) | 2 (<1) |
Anti-PEG Ab positive, n (%) | 18 (8) | 12 (5) | 25 (5) | 27 (5) |
Delayed treatment groups: patients who received placebo in year 1 and switched to peginterferon beta1a in year 2. Pretreatment baseline measure taken at the beginning of year 2 in these groups.
NAb assay was performed only on anti-IFN BAb-positive samples, per tiered assay design; percentages are given as a proportion of the total safety population.
Ab, antibody; BAb, binding antibody; IFN, interferon; NAb, neutralizing antibody; PEG, polyethylene glycol.